Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.37
TFX's Cash to Debt is ranked lower than
80% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. TFX: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
TFX' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.22 Max: 0.93
Current: 0.37
0.06
0.93
Equity to Asset 0.52
TFX's Equity to Asset is ranked lower than
67% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. TFX: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
TFX' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.48 Max: 0.53
Current: 0.52
0.32
0.53
Interest Coverage 5.49
TFX's Interest Coverage is ranked lower than
82% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 44.71 vs. TFX: 5.49 )
Ranked among companies with meaningful Interest Coverage only.
TFX' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 3.42 Max: 6.06
Current: 5.49
2.57
6.06
F-Score: 7
Z-Score: 3.21
M-Score: -2.58
WACC vs ROIC
8.20%
11.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.60
TFX's Operating margin (%) is ranked higher than
86% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. TFX: 17.60 )
Ranked among companies with meaningful Operating margin (%) only.
TFX' s Operating margin (%) Range Over the Past 10 Years
Min: -6.28  Med: 14.16 Max: 17.46
Current: 17.6
-6.28
17.46
Net-margin (%) 14.25
TFX's Net-margin (%) is ranked higher than
86% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. TFX: 14.25 )
Ranked among companies with meaningful Net-margin (%) only.
TFX' s Net-margin (%) Range Over the Past 10 Years
Min: -12.25  Med: 9.55 Max: 21.15
Current: 14.25
-12.25
21.15
ROE (%) 13.15
TFX's ROE (%) is ranked higher than
78% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. TFX: 13.15 )
Ranked among companies with meaningful ROE (%) only.
TFX' s ROE (%) Range Over the Past 10 Years
Min: -10.11  Med: 11.80 Max: 21.44
Current: 13.15
-10.11
21.44
ROA (%) 6.55
TFX's ROA (%) is ranked higher than
74% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. TFX: 6.55 )
Ranked among companies with meaningful ROA (%) only.
TFX' s ROA (%) Range Over the Past 10 Years
Min: -4.96  Med: 5.00 Max: 8.55
Current: 6.55
-4.96
8.55
ROC (Joel Greenblatt) (%) 38.56
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. TFX: 38.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TFX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13.25  Med: 31.40 Max: 44.46
Current: 38.56
-13.25
44.46
Revenue Growth (3Y)(%) -0.30
TFX's Revenue Growth (3Y)(%) is ranked lower than
63% of the 236 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. TFX: -0.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TFX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.9  Med: 1.90 Max: 17.3
Current: -0.3
-14.9
17.3
» TFX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

TFX Guru Trades in Q2 2015

Third Avenue Management 56,069 sh (unchged)
John Keeley 3,170 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 330,700 sh (-4.12%)
Murray Stahl 5,082 sh (-16.36%)
Joel Greenblatt 160,323 sh (-37.72%)
Steven Cohen 111,100 sh (-41.61%)
Jim Simons 105,697 sh (-76.52%)
» More
Q3 2015

TFX Guru Trades in Q3 2015

John Keeley 3,170 sh (unchged)
Third Avenue Management 56,069 sh (unchged)
Jim Simons Sold Out
Murray Stahl 5,017 sh (-1.28%)
Joel Greenblatt 132,561 sh (-17.32%)
Chuck Royce 207,700 sh (-37.19%)
Steven Cohen 23,900 sh (-78.49%)
» More
Q4 2015

TFX Guru Trades in Q4 2015

Jim Simons 40,600 sh (New)
John Keeley 3,170 sh (unchged)
Jerome Dodson Sold Out
Steven Cohen Sold Out
Murray Stahl 4,942 sh (-1.49%)
Chuck Royce 181,800 sh (-12.47%)
Third Avenue Management 45,957 sh (-18.03%)
Joel Greenblatt 85,071 sh (-35.83%)
» More
Q1 2016

TFX Guru Trades in Q1 2016

George Soros 5,800 sh (New)
Paul Tudor Jones 8,620 sh (New)
Jim Simons 154,100 sh (+279.56%)
John Keeley 5,255 sh (+65.77%)
Chuck Royce 181,800 sh (unchged)
Murray Stahl 4,792 sh (-3.04%)
Third Avenue Management 38,457 sh (-16.32%)
Joel Greenblatt 25,631 sh (-69.87%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:VAR, OTCPK:SONVY, NAS:ALGN, OTCPK:WILYY, OTCPK:SDMHF, OTCPK:CHEOY, NAS:ABMD, OTCPK:FSPKF, OTCPK:GGNDF, NAS:NUVA, NAS:IART, OTCPK:EKTAF, NAS:MASI, OTCPK:SHWGF, NAS:LIVN, OTCPK:NHNKY, NYSE:GMED, NYSE:NVRO, NAS:WMGI, NYSE:PEN » details
Traded in other countries:TBH.Germany,
Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Teleflex Inc a Delaware corporation incorporated in 1943. The Company is a provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It markets and sells its products to hospitals and healthcare providers through a combination of its direct sales force and distributors. It manufactures its products at 25 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company operates in following six reportable operating segments: Vascular North America, Anesthesia North America, Surgical North America, EMEA (Europe, Middle East and Africa), Asia and OEM. Vascular North America segment is comprised of North American vascular and interventional access businesses, which offers products that facilitate critical care therapies and other applications. The vascular access products consist of Arrow branded catheters and related devices that are used in procedures, including the administration of intravenous medications and other therapies, the measurement of blood pressure and the withdrawal of blood samples through a single puncture site. The vascular access product portfolio consists of the following products - Arrow Central Venous Catheters; Arrow EZ-IO Intraosseous Vascular Access System; Arrow Peripherally Inserted Central Catheters; Arrow Jugular Axillo-subclavian Central Catheters; VPS G4 Vascular Positioning System; Arrow Arterial Catheterization Sets; and Arrow Percutaneous Sheath Introducers. The interventional access products are used in applications, including dialysis, oncology and critical care therapies. Its interventional access portfolio also includes several Arrow branded products, such as diagnostic and drainage kits, embolectomy balloons, and reinforced percutaneous sheath introducers. Its interventional access products include - Arrow OnControl Powered Bone Marrow / Bone Access System; Arrow Trerotola Percutaneous Thrombectomy Device; Arrow Chronic Hemodialysis Catheters; and Arrow Acute Hemodialysis Catheters. The Anesthesia North America segment is comprised of North American airway management and pain management businesses. The airway management products and related devices consist of - LMA Airways; LMA Atomization; and RUSCH Endotracheal Tubes and Laryngoscopes. The pain management products, which are designed for use in a of surgical and obstetric procedures, consist of - Arrow Epidural Catheters, Needles and Kits; Arrow Peripheral Nerve Block (PNB) Catheters, Pumps, Needles and Kits; AutoFuser Disposable Pain Pumps; and Arrow EZ-IO System. In the Surgical North America the surgical products are designed to provide surgeons with devices for use in sur

Ratios

vs
industry
vs
history
P/E(ttm) 32.25
TFX's P/E(ttm) is ranked lower than
64% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 26.80 vs. TFX: 32.25 )
Ranked among companies with meaningful P/E(ttm) only.
TFX' s P/E(ttm) Range Over the Past 10 Years
Min: 4.99  Med: 18.96 Max: 232.99
Current: 32.25
4.99
232.99
Forward P/E 24.94
TFX's Forward P/E is ranked lower than
52% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 23.53 vs. TFX: 24.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.43
TFX's PE(NRI) is ranked lower than
63% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 27.05 vs. TFX: 33.43 )
Ranked among companies with meaningful PE(NRI) only.
TFX' s PE(NRI) Range Over the Past 10 Years
Min: 14.01  Med: 28.56 Max: 74.07
Current: 33.43
14.01
74.07
Price/Owner Earnings (ttm) 31.01
TFX's Price/Owner Earnings (ttm) is ranked lower than
51% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. TFX: 31.01 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TFX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.84  Med: 14.42 Max: 47.82
Current: 31.01
5.84
47.82
P/B 3.59
TFX's P/B is ranked lower than
61% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. TFX: 3.59 )
Ranked among companies with meaningful P/B only.
TFX' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 1.85 Max: 3.7
Current: 3.59
1.04
3.7
P/S 4.55
TFX's P/S is ranked lower than
66% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. TFX: 4.55 )
Ranked among companies with meaningful P/S only.
TFX' s P/S Range Over the Past 10 Years
Min: 0.71  Med: 1.67 Max: 4.69
Current: 4.55
0.71
4.69
PFCF 30.31
TFX's PFCF is ranked lower than
52% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.54 vs. TFX: 30.31 )
Ranked among companies with meaningful PFCF only.
TFX' s PFCF Range Over the Past 10 Years
Min: 5.91  Med: 14.76 Max: 51.54
Current: 30.31
5.91
51.54
POCF 25.25
TFX's POCF is ranked lower than
65% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 25.25 )
Ranked among companies with meaningful POCF only.
TFX' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 11.95 Max: 27.22
Current: 25.25
5.22
27.22
EV-to-EBIT 26.43
TFX's EV-to-EBIT is ranked lower than
57% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 21.43 vs. TFX: 26.43 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.1  Med: 16.80 Max: 29.9
Current: 26.43
-40.1
29.9
EV-to-EBITDA 19.47
TFX's EV-to-EBITDA is ranked lower than
57% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 17.77 vs. TFX: 19.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
TFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.3  Med: 11.50 Max: 3794.7
Current: 19.47
-371.3
3794.7
Shiller P/E 40.49
TFX's Shiller P/E is ranked higher than
50% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.47 vs. TFX: 40.49 )
Ranked among companies with meaningful Shiller P/E only.
TFX' s Shiller P/E Range Over the Past 10 Years
Min: 10.92  Med: 20.13 Max: 41.79
Current: 40.49
10.92
41.79
Current Ratio 1.61
TFX's Current Ratio is ranked lower than
77% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. TFX: 1.61 )
Ranked among companies with meaningful Current Ratio only.
TFX' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.99 Max: 5.2
Current: 1.61
1.46
5.2
Quick Ratio 1.11
TFX's Quick Ratio is ranked lower than
77% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. TFX: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.26 Max: 4.01
Current: 1.11
0.86
4.01
Days Inventory 144.68
TFX's Days Inventory is ranked lower than
55% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. TFX: 144.68 )
Ranked among companies with meaningful Days Inventory only.
TFX' s Days Inventory Range Over the Past 10 Years
Min: 79.93  Med: 134.66 Max: 143.59
Current: 144.68
79.93
143.59
Days Sales Outstanding 55.54
TFX's Days Sales Outstanding is ranked higher than
69% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.64 vs. TFX: 55.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.03  Med: 56.95 Max: 70.12
Current: 55.54
47.03
70.12
Days Payable 31.18
TFX's Days Payable is ranked lower than
81% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. TFX: 31.18 )
Ranked among companies with meaningful Days Payable only.
TFX' s Days Payable Range Over the Past 10 Years
Min: 26.07  Med: 31.48 Max: 41.11
Current: 31.18
26.07
41.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.79
TFX's Dividend Yield is ranked lower than
73% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. TFX: 0.79 )
Ranked among companies with meaningful Dividend Yield only.
TFX' s Dividend Yield Range Over the Past 10 Years
Min: 0.77  Med: 1.82 Max: 3.48
Current: 0.79
0.77
3.48
Dividend Payout 0.27
TFX's Dividend Payout is ranked higher than
66% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. TFX: 0.27 )
Ranked among companies with meaningful Dividend Payout only.
TFX' s Dividend Payout Range Over the Past 10 Years
Min: 0.17  Med: 0.30 Max: 1.26
Current: 0.27
0.17
1.26
Forward Dividend Yield 0.77
TFX's Forward Dividend Yield is ranked lower than
78% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.78 vs. TFX: 0.77 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.79
TFX's Yield on cost (5-Year) is ranked lower than
76% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. TFX: 0.79 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TFX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.77  Med: 1.82 Max: 3.48
Current: 0.79
0.77
3.48
3-Year Average Share Buyback Ratio -0.50
TFX's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. TFX: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TFX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -1.00 Max: 0.8
Current: -0.5
-2.1
0.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.55
TFX's Price/Projected FCF is ranked lower than
62% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. TFX: 2.55 )
Ranked among companies with meaningful Price/Projected FCF only.
TFX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.12 Max: 2.88
Current: 2.55
0.47
2.88
Price/Median PS Value 2.75
TFX's Price/Median PS Value is ranked lower than
93% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. TFX: 2.75 )
Ranked among companies with meaningful Price/Median PS Value only.
TFX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 0.71 Max: 2.53
Current: 2.75
0.43
2.53
Earnings Yield (Greenblatt) (%) 3.84
TFX's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. TFX: 3.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TFX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.3  Med: 5.70 Max: 9.4
Current: 3.84
3.3
9.4
Forward Rate of Return (Yacktman) (%) 1.26
TFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
68% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. TFX: 1.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TFX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 6.40 Max: 19.1
Current: 1.26
3.1
19.1

More Statistics

Revenue (TTM) (Mil) $1,805
EPS (TTM) $ 5.31
Beta0.94
Short Percentage of Float5.17%
52-Week Range $122.13 - 176.84
Shares Outstanding (Mil)43.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,883 1,999 2,143
EPS ($) 7.08 8.18 7.87
EPS w/o NRI ($) 7.08 8.18 7.87
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 

More From Other Websites
Teleflex to Present Innovative New Vascular Access Technologies at World Congress on Vascular Access... Jun 17 2016
Teleflex to present at Social Media and Critical Care Conference (SMACC) in Dublin, Ireland Jun 10 2016
TELEFLEX INC Files SEC form 8-K, Unregistered Sale of Equity Securities May 31 2016
Teleflex to Present at William Blair 36th Annual Growth Stock Conference May 31 2016
Teleflex to Present at William Blair 36th Annual Growth Stock Conference May 31 2016
Teleflex to Present at First European Emergency Medical Service Congress (“EMS2016”) in... May 26 2016
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Present at the 53rd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 18 2016
Teleflex to Present at the 53rd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 18 2016
TELEFLEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... May 16 2016
IHI Remains Stable in a Sluggish Market May 13 2016
Layoff mixup: Only 84 workers to lose jobs in near term, not 456, company states May 13 2016
TELEFLEX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 12 2016
Teleflex Incorporated Announces Pricing of $400 Million Senior Notes Offering May 11 2016
Teleflex Incorporated Announces Pricing of $400 Million Senior Notes Offering May 11 2016
Teleflex Incorporated -- Moody's rates Teleflex notes Ba3; stable outlook May 11 2016
Teleflex Incorporated Announces Public Offering of $400 Million of Senior Notes May 11 2016
TELEFLEX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)